Page last updated: 2024-10-24

candesartan and Cognition Disorders

candesartan has been researched along with Cognition Disorders in 12 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.

Research Excerpts

ExcerptRelevanceReference
"Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure."9.17Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013)
"We investigated the effect of treatment of hypertension on cognition with the angiotensin-receptor-blocker, candesartan, in a placebo-controlled, double-blind, randomized controlled trial at one center participating in the Study on Cognition and Prognosis in the Elderly."9.13Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. ( Ford, GA; Harrington, F; McKeith, IG; Saxby, BK; Wesnes, KA, 2008)
"Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure."5.17Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013)
"One hundred and five patients eligible for coronary artery bypass graft surgery (65-85 years old, all suffering from hypertension and coronary artery disease, with stable kidney function) were randomized to candesartan (8 mg od) or placebo for between 8 and 11 days prior to surgery."5.14ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting. ( Erdmann, E; Flesch, M; Geissler, HJ; Kessler, G; Knipp, S; Massoudy, P; Philipp, T; Wilhelm, H, 2009)
"We investigated the effect of treatment of hypertension on cognition with the angiotensin-receptor-blocker, candesartan, in a placebo-controlled, double-blind, randomized controlled trial at one center participating in the Study on Cognition and Prognosis in the Elderly."5.13Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. ( Ford, GA; Harrington, F; McKeith, IG; Saxby, BK; Wesnes, KA, 2008)
"Treatment with candesartan markedly increased mRNA expression of angiotensin II type-2 receptor and methyl methanesulfonate sensitive-2 in the brain in KK-A(y) mice, determined by quantitative RT-PCR."1.34Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. ( Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2007)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (58.33)29.6817
2010's4 (33.33)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Kulisevsky, J1
Martínez-Horta, S1
Campolongo, A1
Pascual-Sedano, B1
Marín-Lahoz, J1
Bejr-Kasem, H1
Labandeira-Garcia, JL1
Lanciego, JL1
Puig-Davi, A1
Horta-Barba, A1
Pagonabarraga, J1
Rodríguez-Antigüedad, J1
Hornslien, AG1
Sandset, EC1
Bath, PM1
Wyller, TB1
Berge, E1
Li, Z1
Cao, Y1
Li, L1
Liang, Y1
Tian, X1
Mo, N1
Liu, Y1
Li, M1
Chui, D1
Guo, X1
Marchese, NA1
Artur de laVillarmois, E1
Basmadjian, OM1
Perez, MF1
Baiardi, G1
Bregonzio, C1
Flesch, M1
Knipp, S1
Kessler, G1
Geissler, HJ1
Massoudy, P1
Wilhelm, H1
Philipp, T1
Erdmann, E1
Hajjar, I1
Hart, M1
Chen, YL1
Mack, W1
Milberg, W1
Chui, H1
Lipsitz, L1
Sever, P1
Kumagai, H1
Onami, T1
Takimoto, C1
Iigaya, K1
Saruta, T1
Kim, S1
Kohara, K1
Tsukuda, K1
Mogi, M1
Li, JM1
Iwanami, J1
Min, LJ1
Sakata, A1
Fujita, T1
Iwai, M1
Horiuchi, M1
Saxby, BK1
Harrington, F1
Wesnes, KA1
McKeith, IG1
Ford, GA1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Scandinavian Candesartan Acute Stroke Trial[NCT00120003]Phase 32,500 participants (Anticipated)Interventional2005-06-30Completed
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)[NCT00605072]Phase 253 participants (Actual)Interventional2008-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Blood Flow Velocity, Sitting

This reports the change in the least square mean from baseline to 12 months, adjusted for age (NCT00605072)
Timeframe: Baseline-12 months

Interventioncm/sec (Least Squares Mean)
ACEI (Lisinopril)-0.3
ARB (Candesartan)-2.85
HCTZ0.35

Blood Pressure Outcome: Systolic BP

Blood pressure was measured as follows: the participant was in the sitting position, rested for 5 minutes, no caffeine or smoking 2 hours prior to measurement, using appropriate cuff size (covering 60% of upper arm length and 80% of arm circumference), correct cuff placement (1-2 inches above brachial pulse on bare arm), and the bell of the stethoscope. The systolic blood pressure was defined as the pressure corresponding to the first korotkoff sounds (K1) and the diastolic as the pressure corresponding to the last korotkoff sound (K5). Blood pressure was measured in both arms and recorded (NCT00605072)
Timeframe: Baseline-12 months

Interventionmm Hg (Least Squares Mean)
ACEI (Lisinopril)28
ARB (Candesartan)27
HCTZ21

Cognitive Assessment: Forward Digit Span Test

This test consists of series of digits of increasing length, some of which are recited as presented, and some of which are to be recited in reversed order. The forward digit span score ranges from 0 (ie cannot repeat two digits) to 8 ( participant can repeat up to 8 digits) (NCT00605072)
Timeframe: Baseline-12 months

Interventionnumber of digits repeated (Least Squares Mean)
ACEI (Lisinopril)-0.3
ARB (Candesartan)0.02
HCTZ-0.04

Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall

This is a 12-item list learning test in which individuals are presented three learning and recall trials followed by a delayed recall and 24 item recognition test. The HVLT-R has been identified as an ideal memory measure for elderly patients, and appropriate reliability and validity have been shown in older individuals. The test score is the number of correct answers in the delayed recall ( score range 0-12) (NCT00605072)
Timeframe: Baseline-12 months

Interventionnumber words remembered (Least Squares Mean)
ACEI (Lisinopril)-1
ARB (Candesartan)-2
HCTZ-3

Cognitive Assessment: Trail Making Test Part B

This test requires the connection of sequentially numbered circles (A), and the connection of circles marked by numbers and letters in alternating sequence (B). This test is considered a benchmark of executive function. The test score is the time required to complete the task in seconds. (NCT00605072)
Timeframe: Baseline-12 months

Interventionseconds (Least Squares Mean)
ACEI (Lisinopril)-14
ARB (Candesartan)17
HCTZ4

Reviews

4 reviews available for candesartan and Cognition Disorders

ArticleYear
The SCOPE trial. Study on Cognition and Prognosis in the Elderly.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2002, Volume: 3, Issue:2

    Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Disorders; Humans; Hype

2002
[Organ protection by angiotensin II receptor blockers].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals;

2004
[Scope].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 3

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2004
[Study on cognition and prognosis in the elderly].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 6

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida

2006

Trials

6 trials available for candesartan and Cognition Disorders

ArticleYear
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease.
    Parkinsonism & related disorders, 2023, Volume: 110

    Topics: Benzimidazoles; Cognition Disorders; Cognitive Dysfunction; Humans; Neuropsychological Tests; Parkin

2023
Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial.
    Stroke, 2013, Volume: 44, Issue:7

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Diso

2013
ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2009, Volume: 98, Issue:1

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds

2009
Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial.
    Archives of internal medicine, 2012, Mar-12, Volume: 172, Issue:5

    Topics: Age Factors; Aged; Benzimidazoles; Biphenyl Compounds; Blood Pressure Determination; Cognition; Cogn

2012
The SCOPE trial. Study on Cognition and Prognosis in the Elderly.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2002, Volume: 3, Issue:2

    Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Disorders; Humans; Hype

2002
Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial.
    Neurology, 2008, May-06, Volume: 70, Issue:19 Pt 2

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Antihypertensive Age

2008

Other Studies

3 other studies available for candesartan and Cognition Disorders

ArticleYear
Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction.
    Biochemical and biophysical research communications, 2014, Jun-20, Volume: 449, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Ba

2014
Brain Angiotensin II AT1 receptors are involved in the acute and long-term amphetamine-induced neurocognitive alterations.
    Psychopharmacology, 2016, Volume: 233, Issue:5

    Topics: Amphetamines; Angiotensin II Type 1 Receptor Blockers; Animals; Avoidance Learning; Behavior, Animal

2016
Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose;

2007